SEARCH:   Advanced

Blood, 1 August 2006, Vol. 108, No. 3, pp. 1007-1012. Prepublished online as a Blood First Edition Paper on March 28, 2006; DOI 10.1182/blood-2005-11-4757. This Article Full Text (PDF) All Versions of this Article: 2005-11-4757v1 108/3/1007    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhang, Z. Articles by Waldmann, T. A Search for Related Content PubMed PubMed Citation Articles by Zhang, Z. Articles by Waldmann, T. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 2, 2005 Accepted March 11, 2006 Effective treatment of a murine model of adult T cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizmab) directed towards CD25 Zhuo Zhang, Meili Zhang, Kayhan Garmestani, Vladimir S Talanov, Paul S Plascjak, Barbara Beck, Carolyn K Goldman, Martin W Brechbiel, and Thomas A Waldmann* Metabolism Branch, Center for Cancer Research, National Institute of Health, National Cancer Institute, Bethesda, MD, USA Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Clinical Center, National Institutes of Health, Bethesda, MD, USA * Corresponding author; email: tawald{at}helix.nih.gov. Adult T-cell leukemia (ATL) consists of an overabundance of T cells, which express CD25. Therapeutic efficacy of astatine-211 labeled murine monoclonal antibody 7G7/B6 alone and in combination with daclizmab was evaluated in NOD/SCID mice injected with MET-1 human T-cell leukemia cells.. 7G7/B6 and daclizmab are directed toward different epitopes of CD25. Either a single dose of 12 µCi 211At-7G7/B6 per mouse given i.v. or receptor saturating doses of daclizmab given at 100 µg weekly for 4 weeks i.v. inhibited tumor growth as monitored by serum levels of human -2-microglobulin, and by prolonged survival of the leukemia-bearing mice as compared with the control groups (P < .0001). The combination of two agents enhanced the antitumor effect, when compared with groups treated with 12 µCi of 211At-7G7/B6 (P < .05) or daclizmab alone (P < .05). The median survival duration of the control group (PBS) was 62.6 days and was 61.5 days in the radiolabeled nonspecific antibody 211At-11F11 treated group. In contrast, there were 91% of mice in the combination group that survived through day 94. These results that demonstrate a significantly improved therapeutic efficacy by combining 211At-7G7/B6 with daclizmab support a clinical trial of this regimen in patients with ATL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020